Reflective Blogging

  CAR T cell therapy is the most commonly used form of complementary immunosuppression today in regions such as UK, US, and Italy, and many people are aware of it through the publicity and marketing efforts of global pharmaceutical companies. Chimeric antigen receptor T cells (CAR T cell) are genetically engineered in a lab to generate a synthetic T cell receptor for application in immunotherapy. Many patients are now using this treatment for their chronic illnesses such as chronic hepatitis, cancer, infectious mononucleosis, Crohn's disease, etc. When cancerous cells invade the body, they secrete a protein called interferon-gamma, which can damage healthy cells. This causes the healthy cells to secrete antibodies called macrophages, which chase the interferon-gamma away. This is how the immune system reacts to cancer and results in remission of the illness. The CAR T cells are introduced into the patient's body at this time, and once they start to recognize the cancerous cel...

  Bispecific antibodies are artificial proteins that find application in the field of cancer immunotherapy. High prevalence of cancer has led to significant development in these antibodies. For instance, according to the World Health Organization’s Globocan 2018, Germany recorded 608,742 cases of cancer 247,462 cancer-related deaths in 2018. However, there are several issues in producing adequate quantities of bispecific antibodies. One of the biggest challenges in the development of these antibodies is producing adequate quantities by conventional biotechnological methods, including the chemical and hybridoma processes. Recently, there has been a major advancement in biotechnological approaches to improve the quality of bispecific antibodies, specifically artificial proteins, in the laboratory. Recent developments have resulted in the production of large numbers of artificial proteins that are more reliable and more potent than those developed in the past. The synthetic versions...